Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1)

Request For Quotation
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) Suppliers list
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Dideu Industries Group Limited  
Tel: +8617392712697
Email: 1022@dideu.com
Company Name: Guangzhou Younan Technology Co., Ltd  
Tel: 020-82000279 18988941452
Email: YN_research@163.com
Company Name: Aladdin Scientific  
Tel:
Email: tp@aladdinsci.com
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) Basic information
Product Name:Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1)
Synonyms:Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1)
CAS:141284-73-3
MF:C15H20F3N3O3S.Na
MW:402.39
EINECS:
Product Categories:
Mol File:141284-73-3.mol
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) Structure
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) Chemical Properties
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) Usage And Synthesis
UsesFuzapladib (IS-741) sodium, an orally active leukocyte-function-associated antigen type 1 (LFA-1) activation inhibitor, is a leukocyte adhesion molecule. Fuzapladib sodium is also a phospholipase A2 (PLA2) inhibitor. Fuzapladib sodium exerts anti-inflammatory effects by inhibiting leukocyte migration into the inflammatory site[1][2].
in vivo

Fuzapladib sodium (IS-741 sodium) (p.o., 50 mg/kg, 7 days) inhibits neutrophil infiltration into inflamed lesions, and is effective for attenuating rat trinitrobenzene sulfonic acid (TNBS) ileitis[4].

Animal Model:Rats[2]
Dosage:50 mg/kg
Administration:P.o.; for 7 days
Result:Significantly reduced myeloperoxidase (MPO) activity and mucosal IL-8 levels in rat ileum, reduced polymorphonuclear cells and Mac-1 positivity Infiltration of cells into inflammatory lesions, effectively alleviated trinitrobenzenesulfonic acid (TNBS)-induced ileitis.
References[1] Noriyuki Kaji, et al. Fuzapladib reduces postsurgical inflammation in the intestinal muscularis externa. J Vet Med Sci. 2023 Sep 21. DOI:10.1292/jvms.23-0257
[2] C Bassi. IS-741 (Ishihara Sangyo). Curr Opin Investig Drugs. 2001 Apr;2(4):510-2. PMID:11566008
[3] Shikama H, et al. Effect of IS-741 on cell adhesion between human umbilical vein endothelial cells and HL-60 cells. Biol Pharm Bull. 1999 Feb;22(2):127-31. DOI:10.1248/bpb.22.127
[4] Tetsuya Fukunaga, et al. A novel diamino-pyridine derivative (IS-741) attenuates rat ileitis induced by trinitrobenzene sulfonic acid. J Gastroenterol. 2003;38(5):451-9. DOI:10.1007/s00535-002-1081-8
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) Preparation Products And Raw materials
Tag:Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1)(141284-73-3) Related Product Information
Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]-, sodium salt (1:1) IS 741 Integrin alpha V beta 8 protein, human (HEK293, His-AVI) Neomycin sulfate Integrin alpha V beta 6 protein, human (HEK293, FLAG-His) Integrin alpha V beta 8 protein, human (biotinylated, HEK293, His-AVI)